ArticleScientific reports2025
Association of remnant cholesterol with new-onset hypertension among middle-aged and older adults in China.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Association between the remnant cholesterol and the risk of new-onset chronic diseases: evidence from CHARLS.Diabetology & metabolic syndrome · 2026Article
- Association between remnant cholesterol and isolated diastolic hypertension in young adults: a cross-sectional study in China.BMC cardiovascular disorders · 2026Article
- A Narrative Review of Remnant Cholesterol as an Independent Atherogenic Lipoprotein in Type 2 Diabetes: Pathophysiology and Clinical Implications.Therapeutics and clinical risk management · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Although remnant cholesterol has been associated with cardiovascular disease, the risk of remnant cholesterol and blood pressure remains unclear. This study aimed to investigate the association between remnant cholesterol and new-onset hypertension. We used middle-aged and older adults aged ≥ 45 years from the first three waves of the China Health and Retirement Longitudinal Study (CHARLS). Estimated remnant cholesterol was calculated as total cholesterol minus high-density lipoprotein cholesterol minus low-density lipoprotein cholesterol. Multiple linear regression analysis and Cox proportional hazards modeling were used to assess the association between remnant cholesterol levels and blood pressure levels and new-onset hypertensive events, respectively. Nonlinear associations were assessed using restricted cubic spline models. A total of 3,044 participants were included, and 839 new-onset hypertensive events (76.5 events per 1000 person-years) were documented during a median follow-up period of 4.0 years. After adjustment for age, sex, lifestyle factors, and other cardiovascular risk factors, compared with participants with normal-range (< 31 mg/dl), those with significantly elevated (≥ 46 mg/dl) remnant cholesterol had elevated systolic blood pressure by 2.36 (95% confidence interval [95% CI]: 0.55, 4.17) mmHg and diastolic blood pressure by 1.66 mmHg (95% CI: 0.47, 2.84), and the risk of new-onset hypertension was 28% higher (hazard ratio [HR]: 1.28; 95% CI: 1.03, 1.59), with no significant association observed in the mildly elevated group (31-46 mg/dl). This association showed similar results in different subgroups. Elevated remnant cholesterol is significantly associated with blood pressure levels and risk of new-onset hypertension, suggesting that remnant cholesterol might be a potential therapeutic target for hypertension prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.